Linklaters advises the European Innovation Council Fund (EIC Fund) on its participation in the Series A equity funding round of Antofénol SAS
Linklaters has advised the EIC Fund on its participation in the €6.3 million Series A equity funding round of Antofénol SAS. The EIC Fund has invested alongside the Caisse des Dépôts et Consignations (CDC), ERPIM, EIT Food and other new and existing investors.
Antofénol is a French-based company specialised in the design and production of eco-extraction solutions and other solutions for use in cosmetics, nutraceutical and biocontrol, developing a range of natural, eco-conscious and anti-microbial products derived from agricultural waste.
Established in June 2020, the EIC Fund is a breakthrough initiative of the European Commission to make direct equity and quasi-equity investments (between €500,000 and €15m) in European high impact and deep tech start-ups and scale ups.
Linklaters recently advised the EIC Fund on its investments in Minuendo AS, Demeta SAS, Lixea OÜ, Hiber B.V., EpiEndo Pharmaceuticals ehf., NIL Technology ApS and Corwave SA.
The Linklaters team was led by Darko Adamovic, Partner, Energy & Infrastructure and Mehdi Boumedine, Counsel, Corporate with Margaux Sartre, Associate, Corporate.